Stock futures are trading higher this morning, driven by strong optimism that the Federal Reserve will cut rates again soon even as the government shutdown drags on and disrupts key economic data releases.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
With nonfarm payrolls datum postponed, markets are leaning on alternative indicators, which currently suggest softening in the labor market and bolster the case for further easing. The broader backdrop remains supportive as equities reached fresh highs overnight and inflows into U.S. stock funds surged, reflecting appetite for growth exposure in this rate-cut environment.
Gold is again in focus, trading near record levels as investors seek refuge amid policy uncertainty and weaker interest rate expectations. Meanwhile, oil is under pressure, on pace for its third consecutive weekly loss as reports suggest potential OPEC+ supply increases.
In pre-market trading, S&P 500 futures rose 0.07%, Nasdaq futures rose 0.06% and Dow futures rose 0.13%.
Check out this morning’s top movers from around Wall Street, compiled by The Fly.
HIGHER –
- Ovid Therapeutics (OVID) up 22% after pricing a private placement for up to $175M in gross proceeds
- Alto Neuroscience (ANRO) up 4% after announcing that the FDA has granted fast track designation to ALTO-101 for the treatment of cognitive impairment associated with schizophrenia
- Rumble (RUM) up 12% after announcing the introduction of a new subscription bundle combining Rumble Premium with Perplexity Pro and the promotion of Perplexity’s new product Comet across the Rumble ecosystem
LOWER –
- GameStop (GME) down 5% after filing an automatic mixed securities shelf
- Apple (AAPL) down 1% after Jefferies downgraded shares to Underperform with a price target of $205.16, down from $205.82
- Tronox (TROX) down 3% after JPMorgan downgraded shares to Neutral
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANRO:
- Alto Neuroscience granted fast track designation for ALTO-101
- Alto Neuroscience initiated with a Buy at Chardan
- Innovative Biomarker Strategy and Promising Pipeline Drive Buy Rating for Alto Neuroscience
- Innovative Precision Psychiatry and Strong Financials Justify Buy Rating for Alto Neuroscience
- Alto Neuroscience announces results from replication study